Introduction:
The cytoprotective effects of activated protein C (aPC) are well established, but the underlying mechanism remains a matter of debate 1, 2 . The uncertainty of aPC-dependent signaling stems from the initial observation that aPC conveys cytoprotective effects via PAR-1, the same receptor through which thrombin (at concentrations >0.1 nM) mediates opposing effects 1 . The physiological relevance of aPC dependent PAR-1 activation has been further questioned based on kinetic studies showing that aPC is ~10 4 -fold less potent than thrombin in regard to PAR-1 cleavage 2 . Specificity of aPC mediated cytoprotection has been attributed to the co-receptor EPCR 3 . The recent identification of further coreceptors mediating aPC dependent effects, such as EDG1 or ApoER2, and the organization of these receptor complexes in lipid rafts provided new insight into mechanisms of aPC dependent cytoprotection [4] [5] [6] [7] .
We and others have recently identified a nephroprotective role of aPC [8] [9] [10] . In experimental diabetic nephropathy aPC prevents apoptosis of endothelial cells and podocytes, the cellular constituents of the glomerular filtration barrier 8 .
Glucose induced endothelial cell apoptosis is prevented by aPC involving activation of PAR-1 and EPCR 8 . Conversely, the receptors and the signaling mechanism underlying the cytoprotective, antiapoptotic effect of aPC in podocytes remains elusive.
In the course of our studies we observed that podocytes lack EPCR, but express PAR-3. In renal glomeruli expression of PAR-3 is predominantly localized to podocytes. PAR-3 is a potential receptor through which aPC may convey cytoprotection, as aPC mediated neuroprotection depends at least in part on PAR-3 in in vivo and in vitro models of neuronal damage or NMDA induced apoptosis [11] [12] [13] . However, insights into the mechanism of aPC / PAR-3 mediated cytoprotection are lacking. This may be attributable to PAR-3's apparent inability to directly alter cellular signaling. In regard to thrombin / PAR-3 signaling this dogma has been recently challenged 14 . Other potential mechanism of thrombinFor personal use only. on October 24, 2017 . by guest www.bloodjournal.org From PAR-3 dependent intracellular signaling include interaction of PAR-3´s tethered ligand with other PAR´s (PAR-1, PAR-2), activation of PAR-4 following binding of thrombin to the hirudin-like sequence of PAR-3, or allosterical modulation of Gprotein function in constitutively present PAR-heterodimers [15] [16] [17] [18] [19] [20] . These insights into mechanisms of PAR-3 dependent signaling are derived from studies using either thrombin or receptor activating peptides as PAR-3 agonists, while studies evaluating the mechanism of aPC signaling via PAR-3 are lacking.
To identify the receptors and signaling mechanism involved in aPC mediated podocyte protection we employed immortalized human and mouse podocytes.
We show that aPC dependent inhibition of podocyte apoptosis requires cleavage of the extracellular N-terminal end of PAR-3 and heterodimerization of PAR-3 with PAR-2 (human podocytes) or with PAR-1 (mouse podocytes). Using the LPS (lipopolysaccharide) induced podocyte injury model we demonstrate that aPC requires PAR-3 for maximal podocyte protection in vivo. These findings identify a new mechanism of aPC mediated cytoprotection, which supports podocyte survival and depends on a novel aPC inducible, PAR-3 dependent signaling mechanism.
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Methods:
See supplementary material and method section for further details.
Cell culture
Conditionally immortalized human and mouse wild-type podocytes were cultured as described elsewhere 21, 22 . 23 .
In vivo podocyte injury models:
Animal experiments were conducted following standards and procedures approved by the local Animal Care and Use Committee (Regierungspräsidium Karlsruhe, Germany). For the LPS induced podocyte injury model we used [8] [9] [10] weeks old littermates with an at least 98% C57BL/6 derived genetic background.
A subset of mice was intraperitoneally injected with ultrapure LPS (200 µg/mice in a total volume of 200 µl sterile PBS, InvivoGen). Recombinant human aPC (20 µg/mice) was intravenously injected 6 h and 18 h after the LPS challenge. Mice were placed in metabolic cages for 4 hours to collect urine before kidneys were harvested 24 hours post LPS injection. Proteinuria was determined using
Bradford reagent.
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Determination of apoptosis
Podocytes were serum starved overnight in serum free medium and pre-treated with aPC or activating peptides for 3 h before the addition of PAN (30 µg/ml).
Activated PC was added after every 12 h. Cells were incubated with cleavage blocking anti-PAR-1 (human podocytes: ATAP-2, 10 µg/ml and WEDE15 10 µg/ml; mouse podocytes: H-111, 10 µg/ml), anti-PAR-2 (SAM-11, 10 µg/ml), anti-PAR-3 (H-103, 20 µg/ml), or anti-PAR-4 (H-120, 10 µg/ml) antibodies for 30 min before treatment with APC. PAR agonist peptides (PAR-APs) and control peptide were used at 20 µM concentration. After 36 h of PAN treatment cells were fixed in 4% neutral buffered formalin, washed in PBS, and apoptosis was determined using the TUNEL method as previously described 24 . Briefly, cells were incubated with terminal deoxynucleotidyl transferase in the presence of fluorescein-labeled dUTP (60 min at 37 ο C) and counterstained with Hoechst 33258 (3.5 μ g/ml).
Random images were obtained and the frequency (in percent) of TUNEL-positive cells was determined by a blinded investigator.
Mouse mesangial cells were cultured as described above in 6 well plates. At 50 to 60% confluence, cells were transiently transfected with wild type or mutant PAR-3 expression constructs using Hifect transfection reagent. Cells were treated 24 h after transfection with either 1 µM staurosporine for 6 h in presence or absence of aPC. Cells were fixed and apoptosis was determined using TUNEL method as described above.
Determination of aPC induced PAR-3 cleavage
To determine aPC induced PAR-3 cleavage, mesangial cells were transiently transfected as mentioned above with PAR-3 expression constructs. 24 h after transfection aPC (20 µg/ml) was added to the cells. Fig. 1a,c) . The anti-apoptotic effect was not impaired following pre-incubation of aPC with the antibody HAPC1573, which inhibits specifically its anticoagulant function without impairing the cytoprotective effect (4.4% vs. 10.5% in PAN only, P<0.001, Fig. 1b,c) . Similar results were obtained when inducing podocyte apoptosis with high glucose (30 mM, data not shown). These data establish that aPC cell autonomously inhibits podocyte apoptosis independent of its anticoagulant properties.
PAR-2 and PAR-3 are predominantly expressed in podocytes within human glomeruli
To identify the receptors through which aPC inhibits podocyte apoptosis we first determined the expression of PARs and EPCR in human podocytes. Surprisingly, immortalized human podocytes do not express EPCR (mRNA and protein) and express very low levels of PAR-1 and PAR-4 (mRNA and protein), while PAR-2 and PAR-3 are readily detectable (Fig. 1d) . In human glomeruli PAR-3 and PAR-2 co-localized predominantly with synaptopodin, a podocyte specific marker 25 ( Fig. 1e and Supplementary Fig. S1 , yellow indicating colocalisation). Conversely, upon immunohistochemical analyses PAR-1 and EPCR poorly co-localized with synaptopodin, which is consistent with the absence of EPCR and the low expression of PAR-1 in podocytes in vitro ( Fig. 1e and Supplementary Fig. S1 ). Thus, PAR-2 and PAR-3 are the PARs predominantly expressed in human podocytes.
PAR-3 is required for aPC dependent inhibition of human podocyte apoptosis
This expression pattern raises the question whether aPC mediates its antiapoptotic effects through a mechanism entirely distinct from the established receptor-dependent mechanism in human endothelial cells, which requires PAR-1 and EPCR 3, 8 . These results indicate that aPC inhibits apoptosis in human podocytes by activation of PAR-3.
Considering that the PAR-2 activation peptide was sufficient to prevent apoptosis in human podocytes and that PAR-3 is generally considered to be signaling incompetent we evaluated whether the aPC -PAR-3 mediated antiapoptotic effect depends on PAR-2. To this end we generated stable PAR-2 and PAR- Taken together, the antiapoptotic effect of aPC depends primarily on PAR-3.
Nevertheless, PAR-2 is required in addition to PAR-3 for aPC's antiapoptotic effect in podocytes, indicating an interaction of PAR-2 and PAR-3 in podocytes.
The antiapoptotic effect of aPC requires PAR-2 / PAR-3 dimerization in human podocytes
To determine whether aPC induces dimerization of PAR-2 and PAR-3, human podocytes were treated with aPC and PAR-2/PAR-3 complex formation was determined by co-immunoprecipitation at various time points. Activated PC induced complex formation of PAR-2 and PAR-3, which was first detectable after Fig. 3b) . Thus, aPC induces heterodimerization of PAR-2 and PAR-3, which are both required for its antiapoptotic effect in human podocytes.
PAR-3 cleavage by aPC is required, but not sufficient to inhibit apoptosis
Blocking PAR-3 is sufficient to abolish aPC´s antiapoptotic effect and both aPC and the PAR-3 agonist peptide failed to inhibit apoptosis in PAR-2 KD podocytes.
Based on these observations we hypothesized that aPC binds to PAR-3, Nevertheless, aPC failed to inhibit apoptosis in mesangial cells expressing PAR-3-TEM-1-V5, establishing that the N-terminal extracellular domain of PAR-3 is not sufficient to mediate aPC´s antiapoptotic effect (Fig. 4d ).
Taken together, cleavage of the N-terminal end of PAR-3 is required for aPC´s antiapoptotic effect via PAR-3, but other domains of PAR-3 are additionally required for cross-coupling with PAR-2 and apoptosis inhibition.
Activated PC dependent apoptosis inhibition in podocytes requires caveolin-1
These data identify a novel, PAR-3 dependent mechanism through which aPC inhibits apoptosis in podocytes. In endothelial cells the organization in lipids rafts and the interaction with caveolin-1 are important for aPC mediated cytoprotection via PAR-1 6, 27 . To determine whether the aPC / PAR-3 mediated cytoprotection is likewise dependent on lipids rafts and caveolin-1 in podocytes, we first performed co-immunoprecipitation experiments. In resting podocytes, an interaction of PAR-2 and PAR-3 with caveolin-1 is readily detectable (Fig. 5a,b) . Following treatment with aPC (20 nM, 15 min) PAR-3 dimerized with PAR-2, as shown above, but the association of these receptors with caveolin-1 was decreased, reflecting dissociation of PAR-2 and PAR-3 from caveolin-1 (Fig. 5a,b) . This aPC induced dissociation required intact lipid rafts, as the cholesterol depleting substance MβCD impaired the aPC induced dissociation of PAR-2 and PAR-3 from caveolin-1 and the dimerization of PAR-3 with PAR-2 ( Fig. 5a,b) .
To evaluate the mechanistic relevance of caveolin-1 for the aPC-PAR-3 mediated antiapoptotic effect in podocytes we generated stable caveolin-1 knock Fig. 5e ). Thus, caveolin-1, which is dephosphorylated by aPC and dissociates from PAR-2 and PAR-3, is required for aPC dependent apoptosis inhibition in podocytes.
The antiapoptotic effect of aPC requires PAR-1 / PAR-3 dimerization in mouse podocytes
We next intended to demonstrate the pathophysiological relevance of aPC-PAR- Fig. 6a and Supplementary Fig. S3 ). Unlike in human podocytes, mouse podocytes only weakly express PAR-2 whereas PAR-1 expression is readily detectable (Fig. 6a) . Fig. 6e ). To determine whether aPC cleaves in analogy to the situation in human podocytes mouse PAR-3 we generated a mouse PAR-3 mutant lacking the known cleavage site (S38P, PAR-3-m-V5). In mouse mesangial cells, which lack PAR-3 ( Supplementary Fig. S3 ), murine aPC cleaved mouse V5-tagged wild type PAR-3 (PAR-3-wt-V5), but not the mutant PAR-3 (PAR-3-m-V5, Supplementary Fig. S4 ).
While lacking PAR-3, mouse mesangial cells endogenously express PAR-1 (Supplementary Fig. S3 ), permitting us to determine whether proteolytic cleavage of PAR-3 is required for the interaction with PAR-1. Indeed, PAR-1 / PAR-3 heterodimerization was easily detectable in mesangial cells transfected with wild type PAR-3 (PAR-3-wt-V5), but not in those transfected with the mutant PAR-3 (PAR-3-m-V5, Fig. 6f ).
These results establish that similar to human PAR-3, mouse PAR-3 plays a crucial role in exerting aPC mediated antiapoptotic effect in murine podocytes.
However, unlike in human podocytes, where PAR-3 forms a heterodimer with PAR-2, PAR-3 dimerizes with PAR-1 in mouse podocytes.
APC-PAR-3 signaling is essential in protecting against podocyte injury and proteinuria in vivo
To evaluate the in vivo relevance of PAR-3 for aPC mediated nephroprotection we conducted studies in PAR-3 knock out (PAR-3 -/-) mice. Since C57BL/6 mice are resistant to PAN induced nephropathy 29 we employed a mouse model of LPS induced podocyte injury and proteinuria 30, 31 . Taken together, the in vitro and in vivo results presented within this study identify a novel aPC dependent signaling mechanism protecting against podocyte injury and proteinuria, which is distinct from endothelial cells and requires aPC mediated PAR-3 activation (Supplementary Fig. S5 ).
Discussion:
It is firmly established that aPC mediates cytoprotection in acute and chronic disease through receptor dependent signaling 8, 35 . How aPC mediates cytoprotection in various tissues such as the vasculature, the brain, or the kidney despite activating the same receptor as thrombin, PAR-1, remained enigmatic for a long time. Recent studies shed light on to this conundrum, as they identified a number of co-receptors through which aPC mediates cytoprotection and activates intracellular signaling pathways which differ from those activated by thrombin 4, 5, 7, 36 . In addition, it was recognized that the temporal activation pattern and the concentration of the activating protease determine the consequences of PAR-dependent signaling 37 . In the current study we evaluated aPC dependent signaling in non-endothelial cells. We identify a novel signaling mechanism underlying the cytoprotective effect of aPC in podocytes. Activated PC binds to and cleaves PAR-3 in podocytes, which induces heterodimerization of PAR-3 with PAR-2 (human) or PAR-1 (mouse) in podocytes. The newly identified, aPC dependent PAR interaction in podocytes differs from previously described pathways though which aPC exerts cytoprotection in other cell types. This demonstrates the plasticity and the cellular specificity of the phenomenon aPC mediated cytoprotection.
In agreement with the expression pattern observed in human glomeruli we failed to detect EPCR and observed only weak expression of PAR-1 in immortalized human podocytes in vitro. In immortalized human podocytes aPC must signal independent of EPCR and PAR-1, as blocking either EPCR or PAR-1 does not abolish aPC's antiapoptotic effect. In addition, PAR-1-agonism fails to inhibit podocyte apoptosis. Conversely, PAR-2 and PAR-3, the two receptors predominantly co-localizing with the podocyte specific marker synaptopodin in human glomeruli, are required for aPC's antiapoptotic effect in human podocytes in vitro. This is in striking contrast to the situation in human endothelial cells, where EPCR and PAR-1 are the established bona fide receptors for aPC. . However, these cells do express EPCR and PAR-1, thus a functional role of these receptors in monocytes cannot be excluded, in particular in regard to physiological relevant endpoints, such as apoptosis or cytokine production, which were not evaluated. Given the lack of EPCR and the low expression and functional irrelevance of PAR-1 in regard to apoptosis inhibition in human podocytes the current observations establish for the first time that aPC can mediate cytoprotection independent of both PAR-1 and EPCR, at least in vitro. These findings strongly suggest that the cytoprotective effects of aPC are not depending on the engagement of a specific set of receptors. Rather, aPC engages cell-specific receptors to mediate cytoprotection. Further studies are required to identify co-receptors that may be required for aPC dependent cytoprotection in podocytes.
A functional role of murine and human PAR-3 as a thrombin receptor has been previously proposed, but with the exception of mouse platelets the exact mechanism through which thrombin -PAR-3 mediates cellular signaling remains unknown 11, [13] [14] [15] [16] [18] [19] [20] . In mouse platelets thrombin cleaves the N-terminal extracellular PAR-3 domain, which is sufficient to enhance PAR-4 dependent platelet activation in the absence of PAR-3 / PAR-4 heterodimerization 26 . The aPC dependent mechanism identified in podocytes differs, as PAR-3 mediated cellular signaling requires in addition to the PAR-3 N-terminal extracellular domain other structures of PAR-3 and depends on heterodimerization with PAR-1 / PAR-2. While the heterodimerization partner of PAR-3 following activation by aPC is species specific in podocytes, the function of PAR-3 is comparable in human and murine podocytes. These observations suggest that the expression and function of PAR-3 in podocytes is evolutionarily conserved across species.
The future availability and analyses of mice with podocyte specific PAR-3 deficiency will be invaluable to provide further in vivo evidence for the pivotal role of PAR-3 in podocytes.
In a recent report it was concluded that PAR-3 can signal autonomously in human kidney cells (HEK-293) transfected with PAR-3 14 . While considering a potential role of PAR-1, this study did not investigate a potential role of PAR-2, which, given the current results, is required to conclude that PAR-3 can signal autonomously. Likewise, our observation that ectopic expression of PAR-3 in mesangial cells renders these cells "aPC-sensitive" does not allow concluding that PAR-3 itself is sufficient. Murine mesangial cells lack EPCR, but express PAR-1 and PAR-2, which may function as the required co-receptor. The dependence of PAR-3 signaling on a co-receptor is consistent with the absence of a cytoplasmic domain in PAR-3 known to couple with G-proteins 38 .
How does PAR-3 modulate intracellular signaling without being directly signaling competent? Heterordimerization of PAR-2 or PAR-1 with PAR-3 in podocytes may regulate the recruitment of G-protein, a mechanism established for other seven-transmembrane receptors 39 . Thus, in human endothelial cells thrombin mediated PAR-1 activation in pre-existing PAR-1 / PAR-3 heterodimers promotes Gα13 signaling 18 . In endothelial cells modulation of intracellular signaling via PAR-1 / PAR-3 is independent of PAR-3 cleavage by thrombin and the function of PAR-3 was proposed to be confined to that of an allosteric regulator within constitutively present PAR-1 / PAR-3 heterodimers 18 . The mechanism in podocytes differs, as (1) aPC directly cleaves PAR-3 and (2) aPC induces heterodimerization of PAR-3 with PAR-2 and PAR-1. Activated PC induced PAR heterodimerization is associated with dissociation from and dephosphorylation of caveolin-1. This reflects a dynamic, caveolin-1 associated rearrangement of the receptor complex, as previously shown for other G-protein coupled receptors [40] [41] [42] . Intriguingly, this is reminiscent of the 
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